Journal of Vascular Surgery
Volume 44, Issue 6 , Pages 1198-1204 , December 2006

The association of carotid plaque inflammation and Chlamydia pneumoniae infection with cerebrovascular symptomatology

Presented at the Twenty-ninth Annual Meeting of the Society for Vascular Surgery, Philadelphia, Pa, June 1-4, 2006.

  • Elias A. Kaperonis, MD

      Affiliations

    • Second Department of Propedeutic Surgery, Laiko Hospital, Athens, Greece
    • Corresponding Author InformationReprint requests: Elias A. Kaperonis, 85, G. Zografou St, 15772 Athens, Greece.
    • ,
  • Christos D. Liapis, MD

      Affiliations

    • Second Department of Propedeutic Surgery, Laiko Hospital, Athens, Greece
    • ,
  • John D. Kakisis, MD

      Affiliations

    • Third Department of Surgery, Attikon Hospital, Athens University Medical School, Athens, Greece
    • ,
  • Despina Perrea, MD

      Affiliations

    • “N.S. Christeas” Laboratory of Experimental Surgery and Surgical Research of the University of Athens, Athens, Greece
    • ,
  • Alkiviadis G. Kostakis, MD

      Affiliations

    • Second Department of Propedeutic Surgery, Laiko Hospital, Athens, Greece
    • ,
  • Panayotis E. Karayannakos, MD

      Affiliations

    • Center for Experimental Surgery, Foundation of Biomedical Research, Academy of Athens, Athens, Greece

Received 21 May 2006 ,Accepted 16 August 2006.

References 

  1. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109(Suppl II):2–10
  2. Epstein SE. The multiple mechanisms by which infection may contribute to atherosclerosis development and course. Circ Res. 2002;90:2–4
  3. Campbell LA, Kuo CC. Chlamydia pneumoniae—an infectious risk factor for atherosclerosis?. Nat Rev Microbiol. 2004;2:23–32
  4. Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation. 2000;102:833–839
  5. Prager M, Turel Z, Speidl WS, Zorn G, Kaun C, Niessner A, et al. Chlamydia pneumoniae in carotid artery atherosclerosis (A comparison of its presence in atherosclerotic plaques, healthy vessels and circulating leucocytes from the same individuals). Stroke. 2002;33:2756–2761
  6. Sessa R, Di Pietro M, Schiavoni G, Santino I, Benedetti-Valentini F, Perna R, et al. Chlamydia pneumoniae DNA in patients with symptomatic carotid atherosclerotic disease. J Vasc Surg. 2003;37:1027–1031
  7. Corrado E, Rizzo M, Tantillo R, Muratori I, Bonura F, Vitale G, et al. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions (A 5-year follow-up study). Stroke. 2006;37:482–486
  8. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res. 2001;89:763–771
  9. Sack MN. Tumor necrosis factor-α in cardiovascular biology and the potential role for anti-tumor necrosis factor-α therapy in heart disease. Pharmacol Ther. 2002;94:123–135
  10. Elkind MS, Cheng J, Boden-Albala B, Rundek T, Thomas J, Chen H, et al. Tumor necrosis factor receptor levels are associated with carotid atherosclerosis. Stroke. 2002;33:31–38
  11. Blessing E, Kuo CC, Lin TM, Campbell LA, Bea F, Chesebro B, et al. Foam cell formation inhibits growth of C. pneumoniae but does not attenuate Chlamydia pneumoniae-induced secretion of proinflammatory cytokines. Circulation. 2002;105:1976–1982
  12. Melnick SL, Shahar E, Folsom AR, Grayston JT, Sorlie PD, Wang SP, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Am J Med. 1993;95:499–504
  13. Cook PJ, Honeybourne D, Lip GYH, Beevers G, Wise R, Davies P. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia (The West Birmingham Stroke Project). Stroke. 1998;29:404–410
  14. Espinola-Klein C, Rupprecht H-J, Blankenberg S, Bickel C, Kopp H, Victor A, et al. Impact of infectious burden on progression of carotid atherosclerosis. Stroke. 2002;33:2581–2586
  15. Volanen I, Jarvisalo MJ, Vainionpaa R, Arffman M, Kallio K, Angle S, et al. Increased aortic intima-media thickness in 11-year old healthy children with persistent Chlamydia pneumoniae seropositivity. Arterioscler Thromb Vasc Biol. 2006;26:649–655
  16. Hirashima Y, Kuwayama N, Kubo M, Origasa H, Endo S. Chlamydia pneumoniae infection is not involved in carotid artery stenosis. Atherosclerosis. 2002;163:165–168
  17. Glader CA, Stegmayr B, Boman J, Stenlund H, Weinehall L, Hallmans G, et al. Chlamydia pneumoniae antibodies and high lipoprotein (a) levels do not predict ischemic cerebral infarctions: results from a nested case-control study in Northern Sweden. Stroke. 1999;30:2013–2018
  18. Ngeh J, Anand V, Gupta S. Chlamydia pneumoniae and atherosclerosis—what we know and what we don’t. Clin Microbiol Infect. 2002;8:2–13
  19. Hoymans VY, Bosmans JM, Van Renterghem L, Mak R, Ursi D, Wuyts F, et al. Importance of methodology in determination of Chlamydia pneumoniae seropositivity in healthy subjects and in patients with coronary atherosclerosis. J Clin Microbiol. 2003;41:4049–4053
  20. Neureiter D, Heuschmann P, Stinzing S, Kolominsky-Rabas P, Barbera L, Jung A, et al. Detection of Chlamydia pneumoniae but not of Helicobacter pylori in symptomatic atherosclerotic carotids, associated with enhanced serum antibodies, inflammation and apoptosis rate. Atherosclerosis. 2003;168:153–162
  21. Dowell SF, Peeling RW, Boman J, Carlone GM, Fields BS, Guarner J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis. 2001;33:492–503
  22. Hoymans VY, Bosmans JM, Ursi D, Martinet W, Wuyts FL, Van Marck E, et al. Immunohistostaining assays for detection of Chlamydia pneumoniae in atherosclerotic arteries indicate cross-reactions with non-chlamydial plaque constituents. J Clin Microbiol. 2004;42:3219–3224
  23. Mygind T, Birkelund S, Falk E, Christiansen G. Evaluation of real-time quantitative PCR for identification and quantification of Chlamydia pneumoniae by comparison with immunohistochemistry. J Mic Meth. 2001;46:241–251
  24. Apfalter P, Barousch W, Nehr M, Willinger B, Rotter M, Hirschl AM. No evidence of involvement of Chlamydia pneumoniae in severe cerebrovascular atherosclerosis by means of quantitative real-time polymerase chain reaction. Stroke. 2004;35:2024–2028
  25. Smieja M, Leigh R, Petrich A, Cong S, Kamada D, Hargreave FE, et al. Smoking, season, and detection of Chlamydia pneumoniae DNA in clinically stable COPD patients. BMC Inf Dis. 2002;2:12–18
  26. Pitiriga VCh, Kotsis VT, Alexandrou ME, Petrocheilou-Paschou VD, Kokolakis N, Zakopoulou RN, et al. Increased prevalence of Chlamydophila pneumoniae but not Epstein-Barr antibodies in essential hypertensives. J Hum Hypertens. 2003;17:21–27
  27. Blessing E, Campbell LA, Rosenfeld ME, Kuo CC. Chlamydia pneumoniae and hyperlipidemia are co-risk factors for atherosclerosis: infection prior to induction of hyperlipidemia does not accelerate development of atherosclerotic lesions in C57BL/6J mice. Inf Imm. 2002;70:5332–5334
  28. Kothe H, Dalhoff K, Rupp J, Muller A, Kreuzer J, Maass M, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation. 2000;101:1760–1763
  29. Blanc P, Corsi AM, Gabbuti A, Peduzzi C, Meacci F, Olivieri F, et al. Chlamydia pneumoniae seropositivity and cardiovascular risk factors: The InCHIANTI Study. J Am Geriatr Soc. 2004;52(10):1626–1631
  30. Baltch AL, Smith RP, Ritz WJ, Carpenter AN, Bopp LH, Michelsen PB, et al. Effect of levofloxacin on the viability of intracellular Chlamydia pneumoniae and modulation of proinflammatory cytokine production by human monocytes. Diagn Mirobiol Infect Dis. 2004;50:205–212
  31. Jatta K, Wagsater D, Norgren L, Stenberg B, Sirsjo A. Lipopolysaccharide-induced cytokine and chemokine expression in human carotid lesions. J Vasc Res. 2005;42:266–271
  32. Vainas T, Kurvers HA, Mess WH, de Graaf R, Ezzahiri R, Tordoir JH, et al. Chlamydia pneumoniae serology is associated with thrombosis-related but not with plaque-related microembolization during carotid endarterectomy. Stroke. 2002;33:1249–1254
  33. Muller BT, Huber R, Henrich B, Adams O, Berns G, Siebler M, et al. Chlamydia pneumoniae, herpes simplex virus and cytomegalovirus in symptomatic and asymptomatic high-grade internal carotid artery stenosis (Does infection influence plaque stability?). Vasa. 2005;34:163–169
  34. Kaperonis EA, Liapis CD, Kakisis JD, Dimitroulis D, Papavassiliou VG, Perrea D, et al. Inflammation and Chlamydia pneumoniae infection correlate with the severity of peripheral arterial disease. Eur J Vasc Endovasc Surg. 2006;31:509–515
  35. Hauer AD, de Vos P, Peterse N, ten Cate H, van Berkel TJ, Stassen FR, et al. Delivery of Chlamydia pneumoniae to the vessel wall aggravates atherosclerosis in LDLr-/- mice. Cardiovasc Res. 2006;69:280–288
  36. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation. 2002;106:2428–2433
  37. DeGraba TJ. Expression of inflammatory mediators and adhesion molecules in human atherosclerotic plaque. Neurology. 1997;49(5 Suppl 4):S15–S19
  38. Tang V, Dhirapong A, Yabes AP, Weiss RH. Tumor necrosis factor alpha mediated apoptosis in vascular smooth muscle cells requires p73. Am J Physiol Cell Physiol. 2005;289:C199–C206
  39. Campbell LA, Nosaka T, Rosenfeld ME, Yaraei K, Kuo C-C. TNF-α plays a role in the acceleration of atherosclerosis by Chlamydia pneumoniae in mice. Infect Immun. 2005;73:3164–3165
  40. Kim MP, Gaydos CA, Wood BJ, Hardick JP, Zhang Y, Wahl LM. Chlamydia pneumoniae enhances cytokine-stimulated human monocyte matrix metalloproteinases through a prostaglandin E2-dependent mechanism. Infect Immun. 2005;73:632–634
  41. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation. 1998;98:300–307

 Competition of interest: none.

PII: S0741-5214(06)01493-5

doi: 10.1016/j.jvs.2006.08.029

Journal of Vascular Surgery
Volume 44, Issue 6 , Pages 1198-1204 , December 2006

Article Tools

* Image Usage & Resolution